ACS Central Science · 2023 · 12 citations · 35 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular VirologyAntiviral AgentsAntiviral PharmacologyPeptide Drug DiscoveryPeptidomimetic DesignFusion Inhibitor ResistanceFusion Peptide FunctionHelical ConformationOral Drug BioavailabilitySars-cov-2 InfectionTreatment Of Coronavirus InfectionsViral Fusion InhibitorsViral Fusion Proteins
High Resolution Image Download MS PowerPoint Slide Neutralizing antibodies and fusion inhibitory peptides have the potential required to combat the global pandemic caused by SARS-CoV-2 and its variants. However, the lack of oral bioavailability and enzymatic susceptibility limited their application, necessitating the development of novel pan-CoV fusion inhibitors. Herein we report a series of helical peptidomimetics, d -sulfonyl-γ-AApeptides, which effectively mimic the key residues of heptad repeat 2 and interact with heptad repeat 1 in the SARS-CoV-2 S2 subunit, resulting in inhibiting SARS-CoV-2 spike protein-mediated fusion between virus and cell membranes. The leads also displayed broad-spectrum inhibitory activity against a panel of other human CoVs and showed strong potency in vitro and in vivo . Meanwhile, they also demonstrated complete resistance to proteolytic enzymes or human sera and exhibited extremely long half-life in vivo and highly promising oral bioavailability, delineating their potential as pan-CoV fusion inhibitors with the potential to combat SARS-CoV-2 and its variants.
35
Shuai Xia, Meiqin Liu, Chao Wang et al. · Cell Research · 2020 · 1.4K citations · Full text
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Laura Riva, Shuofeng Yuan, Xin Yin et al. · Nature · 2020 · 856 citations · Full text